# RapidAI

> RapidAI builds FDA-cleared clinical AI software that reads CT, CTA, CT perfusion and MRI scans to flag stroke, aneurysms and pulmonary embolisms in minutes - giving hospital teams a faster path to treatment. The platform began life as the Stanford spin-out iSchemaView and now runs in more than 2,000 hospitals across 100+ countries.

- **Founded:** 2012
- **Headquarters:** San Mateo, California, United States
- **Founders:** Gregory Albers (Co-founder; Professor of Neurology, Stanford), Roland Bammer (Co-founder)
- **Team size:** ~270
- **Products:** Rapid NCCT Stroke, Rapid LVO / Rapid CTA / Rapid CTP, Rapid ICH, Rapid ASPECTS, Rapid MRI
- **Notable:** Used to select patients for the DAWN and DEFUSE 3 trials that expanded the stroke treatment window to 24 hours., First FDA clearance for AI detection of LVO and ICH from non-contrast CT (Rapid NCCT Stroke, 2023)., First neuroimaging product with FDA CADx clearance (Rapid ASPECTS).

## Products & services

- **Rapid NCCT Stroke** — First FDA-cleared module to detect suspected intracranial hemorrhage and large-vessel occlusion from a non-contrast CT.
- **Rapid LVO / Rapid CTA / Rapid CTP** — AI processing of CT angiography and perfusion scans to flag large vessel occlusion and quantify salvageable brain tissue.
- **Rapid ICH** — Automated detection and notification for intracranial hemorrhage.
- **Rapid ASPECTS** — First neuroimaging tool with FDA CADx clearance; scores early ischemic change.
- **Rapid MRI** — Quantitative diffusion and perfusion mismatch maps for advanced patient selection.
- **Rapid Aneurysm / SurgicalPreview** — Aneurysm detection, measurement and longitudinal tracking.
- **Rapid PE** — Detection and notification of suspected central pulmonary embolism on CTPA.
- **Lumina 3D** — FDA-cleared AI 3D head and neck CTA reconstruction.

## Achievements

- Used to select patients for the DAWN and DEFUSE 3 trials that expanded the stroke treatment window to 24 hours.
- First FDA clearance for AI detection of LVO and ICH from non-contrast CT (Rapid NCCT Stroke, 2023).
- First neuroimaging product with FDA CADx clearance (Rapid ASPECTS).
- Deployed across 2,000+ hospitals in 100+ countries.
- Nearly 10 million scans processed.

## Latest updates

- **2025-11** — Announced five new FDA clearances expanding deep clinical AI portfolio.
- **2025-11** — Partnership with Health Holdings Company to expand into Saudi Arabia.
- **2025-02** — FDA 510(k) clearance for Lumina 3D head and neck CTA imaging.
- **2024-12** — Showcased Rapid Enterprise Platform and Navigator Pro at RSNA 2024.
- **2023-07** — Closed $75M Series C led by Vista Credit Partners.
- **2023-04** — FDA clearance for Rapid NCCT Stroke - first AI cleared to triage stroke from a plain CT.
- **2022-01** — Karim Karti (ex-GE Healthcare Imaging CEO, ex-iRhythm COO) named CEO.
- **2020-02** — Rebranded from iSchemaView to RapidAI.

## Links

- Website: https://rapidai.com
- LinkedIn: https://www.linkedin.com/company/rapid-ai
- Twitter/X: https://twitter.com/rapidai
- YouTube: https://www.youtube.com/@RapidAI
- Facebook: https://facebook.com/pg/rapidai/

---

Profile page: https://yespress.io/rapidai
Published by YesPress — https://yespress.io
Last updated: 2026-05-23